Stocks · News reference
Bowhead’s board of directors approved the transaction with American Family.The transaction is targeted to close prior to the end of 2026, subject to customary closing conditions, including receipt of required regulatory
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-19 AccNo: 0001628280-26-057976 Size: 141 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgarMorgan Stanley analyst Bob Huang maintains Bowhead Specialty Hldgs (NYSE:BOW) with a Equal-Weight and raises the price target from $30 to $34.
Read original at benzingaRBC Capital analyst Rowland Mayor downgrades Bowhead Specialty Hldgs (NYSE:BOW) from Outperform to Sector Perform and lowers the price target from $38 to $34.
Read original at benzingaHalper Sadeh LLC, an investor rights law firm, is investigating three major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations involve Supernus Pharmaceuticals' sale to Indivior, Integer Holdings' acquisition by KKR, and Bowhead Specialty Holdings' sale to American Family Mutual Insurance. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.
Read original at globenewswire-inc